Registry of pediatric proton and photon radiation therapy
Official title: Pediatric Radiation Therapy Registry
Run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07129317 · Data updated 2026-11-12
This registry will collect detailed 3D radiation dose data and health outcomes from children and young adults treated with proton or photon therapy to see how treatment type relates to long-term side effects and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Years to 26 Years |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Washington D.C., District of Columbia and 1 other locations) |
| Status | Recruiting |
| Started | October 31, 2025 |
| Main results expected | September 2035 |
| Study ends | September 2040 |
| Registry record updated | November 5, 2025 |
| Trial ID | NCT07129317 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and young adults up to 26 years old who receive proton or photon radiation at the participating Johns Hopkins sites are ideal candidates.
✕Probably not a fit
Patients older than 26, those not receiving radiation therapy, or those treated outside the participating centers would not benefit from enrolling.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Johns Hopkins Pediatric Radiation Oncology Program will enroll pediatric and young adult patients treated with proton or photon radiation at participating centers and record their full 3D radiation dosimetry. Baseline clinical data, disease characteristics, toxicity reports, and patient-reported quality of life measures will be captured and followed over time. The registry links spatial dose distributions to longitudinal health outcomes to enable future comparisons between proton and photon treatments. Collected data will support clinical quality management and research into treatment-related late effects.
Why it matters
Potential benefit: If successful, the registry could help clinicians choose radiation approaches that reduce long-term toxicity and improve quality of life for young patients.
How similar studies have gone: Other pediatric radiation registries and long-term follow-up efforts exist, but few capture complete 3D dosimetry across both proton and photon therapies, so this approach is partly novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Treatment with either proton or photon radiation therapy. Exclusion Criteria: * Greater than 26 years old
Where it's running
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States Recruiting -
Johns Hopkins Hospital
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Sahaja Acharya, MD — SKCCC Johns Hopkins Medical Institution
- Study coordinator: Ethan Arnone, BS
- Email: earnone3@jh.edu
- Phone: 2029192533
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma
This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.
-
Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma
This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.
-
Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma
This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.
-
Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers
This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.
-
AYA Sarcoma Survivors: Personalized Exercise Program Pilot
This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.
-
Fluorescence-guided surgery to reduce unexpected positive margins in high-grade sarcoma
This phase II trial tests whether adding fluorescence-guided surgery with indocyanine green can lower unexpected positive margins in patients with high-grade sarcoma compared to standard surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.